PLX EBITDA Margin
Protalix Biotherapeutics Inc · EBITDA Margin
PLX EBITDA Margin
Latest reported28.95%period ending
PLX Quarterly EBITDA Margin (0.00% → 28.95%)
Quarterly ebitda margin
High-resolution chart · PNG
PLX ebitda margin history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | EBITDA Margin |
|---|---|
| 28.9505% | |
| 64.4089% | |
| -43.9158% | |
| 15.635% | |
| 11.5213% | |
| -33.4223% | |
| 42.0244% | |
| 24.8956% | |
| -11.7708% | |
| -107.2839% | |
| -50.9155% | |
| -9.2218% | |
| 60.5702% | |
| -20.9324% | |
| -26.5173% | |
| -18.7196% | |
| -50.7597% | |
| -8.6913% | |
| -54.5912% | |
| -12.4772% | |
| -136.1444% | |
| -26.7933% | |
| 16.4606% | |
| -20.0463% | |
| -17.0329% | |
| 24.3555% | |
| 15.7216% | |
| -7.6432% | |
| -44.5579% | |
| -47.313% | |
| 44.6221% | |
| -25.1317% | |
| -129.2476% | |
| -100.7907% | |
| -505.2248% | |
| -96.7579% | |
| 62.7399% | |
| -1,958.0824% | |
| -395.2907% | |
| -126.2741% | |
| -528.2646% | |
| -1,046.539% | |
| 97.6329% | |
| -75.2138% | |
| -369.3114% | |
| -280.1418% | |
| -455.3468% | |
| -144.8341% | |
| -165.4877% | |
| -75.877% | |
| -828.6988% | |
| -141.2623% | |
| -193.7337% | |
| -85.2067% | |
| -19,264.5833% | |
| -86.2338% | |
| 41.7689% | |
| -137.7414% | |
| -335.5207% | |
| -695.2297% | |
| -989.9215% | |
| -69.3333% | |
| -1,459.4388% | |
| -64.6671% | |
| -776.8624% | |
| -650.5697% | |
| -3,719.5876% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| -6,069.3333% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% |